Northrop Grumman CORP /DE/ Form 4 insider transactions

Mark A Welsh Iii, a Director of Northrop Grumman Corp /De/, sold 95 shares of common stock on August 3, 2026.

Northrop Grumman Director Marianne Catherine Brown reported a transaction involving the acquisition of 91 shares of common stock.

Northrop Grumman Director Arvind Krishna acquired 71 shares of common stock on June 30, 2026, as part of a deferred stock unit plan.

Director Mary Winston of Northrop Grumman Corp. reported a transaction involving common stock on May 20, 2026.

Mark A. Welsh III, a Director at Northrop Grumman Corp, reported a transaction involving common stock on May 20, 2026.

Northrop Grumman Director James S. Turley acquired 349 shares of common stock on May 20, 2026, as part of a deferred stock unit plan.

Thomas M. Schoewe, a Director at Northrop Grumman Corp, acquired 349 shares of common stock on May 20, 2026, through a deferred stock unit plan.

Director Gary Roughead reported a transaction involving 349 shares of Northrop Grumman common stock on May 20, 2026.

Kimberly A. Ross, a Director at Northrop Grumman Corp, reported a transaction involving common stock on May 20, 2026.

Arvind Krishna, a Director at Northrop Grumman Corp, acquired 349 shares of common stock on May 20, 2026, valued at $552.17 per share.

Christopher W. Grady, a Director at Northrop Grumman Corp, reported a transaction involving common stock on May 20, 2026.

Northrop Grumman Director Marianne Catherine Brown acquired shares of common stock through a deferred stock unit plan.

David P. Abney, a Director at Northrop Grumman Corp, acquired 349 shares of common stock through a deferred stock unit plan.

Mark A. Welsh III, a Director at Northrop Grumman Corp, reported the sale of common stock totaling 147 shares for an aggregate price of approximately $84,000, executed under a Rule 10b5-1 trading plan.

Director Marianne Brown acquired 68 shares of Northrop Grumman common stock through a deferred stock unit plan.

Director Arvind Krishna acquired 53 shares of Northrop Grumman common stock through a deferred stock unit plan.

Northrop Grumman's Corporate VP & General Counsel, Kathryn G. Simpson, sold 873 shares of common stock for $745 per share under a pre-arranged 10b5-1 trading plan.

Northrop Grumman's Corporate VP and General Counsel, Kathryn G. Simpson, sold 194 shares of common stock for $727.62 per share, as part of a pre-arranged trading plan.

Northrop Grumman director Christopher W. Grady deferred 71 shares of common stock into a stock unit account under a pre-arranged plan.

Northrop Grumman's CVP & President of Defense Systems, Benjamin R. Davies, sold a significant portion of common stock following the vesting of restricted stock rights.

A Northrop Grumman executive reported the vesting of restricted stock rights and a subsequent sale of shares for tax purposes.

A Northrop Grumman Corp. executive reported the vesting of restricted stock rights and subsequent sales of common stock.

Northrop Grumman's CVP & Pres Aeronautics Systems, Thomas H. Jones, reported the vesting of Restricted Stock Rights and subsequent share transactions.

Northrop Grumman CEO Kathy J. Warden reported the vesting of restricted stock rights and subsequent tax-related share disposition.

Northrop Grumman's Corporate VP & General Counsel, Kathryn G. Simpson, reported the acquisition and subsequent sale of common stock, including shares sold under a pre-arranged 10b5-1 trading plan.

Roshan S. Roeder, CVP & President of Mission Systems at Northrop Grumman, reported the vesting of restricted stock rights and subsequent sale of common stock.

A Northrop Grumman Corp executive reported routine stock acquisitions and disposals related to compensation plans, including performance-based awards settling at 148% of target.

Northrop Grumman's CVP & President of Aeronautics Systems, Thomas H. Jones, reported the acquisition of common stock and new grants of restricted performance and stock rights.

Kathryn G. Simpson, Northrop Grumman's Corp VP & General Counsel, reported acquisitions and dispositions of common stock and new grants of restricted performance and stock rights.

Kathy J. Warden, Northrop Grumman's Chair, CEO, and President, reported significant equity transactions including the vesting and settlement of performance stock rights and new grants.